SIGNALCHEM AWARDED TOP 10 CANADA CONTRACT RESEARCH ORGANIZATION COMPANIES 2022

---

SignalChem Lifesciences Corp. was celebrated last December in the annual listing of top 10 companies in Canada that are at the forefront of providing Contract Research Organization (CRO) services and transforming businesses worldwide.

“We are humbled and honoured to be recognized as one of the top CROs in Canada and it has demonstrated that we have been heading in the right direction as an institution that cares deeply about research.” commented by Mr. Jun Yan, Chairman and President of SignalChem Lifesciences Corp..

The award was presented by Pharma Tech Outlook who is a leading business magazine in the U.S with a global reach of subscribers and readers within the Drug Discovery industry.

“This recognition will be a great platform to showcase SignalChem's uniqueness and innovations to the vast readership base of Pharma Tech Outlook”, stated by Judy Morton from Pharma Tech Outlook.

SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Its unique business model has been built upon four important pillars: Drug Discovery and Development, the Bioreagents and Research Services business, In-vitro Diagnostic Development and Plant Biosynthesis System. A group of scientists with extraordinary expertise and experience in protein engineering and drug discovery are working together cohesively to provide the best products and services to its customers around the world and to maximize the efficiency of its own drug discovery efforts.

---